RVTY · Revvity Inc
Price
Snapshot
50 fields · last close| Market Cap | $17.03B |
| P/E | 71.70 |
| Float | 111.2M |
| Beta | 1.09 |
| Volatility | 27.3% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.5 |
| Price | 153.02 |
| Change | +0.25% |
| Prev Close | 152.64 |
| Open | 154.44 |
| Day Low | 151.61 |
| Day High | 155.50 |
| Avg Vol | 2 |
| Avg $ Vol | $265.3M |
| 52W High | 166.25 |
| 52W Low | 81.22 |
| 52W Pos | 84.4% |
| From High | −7.96% |
| From Low | +88.40% |
| Max DD 1Y | −30.14% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.04% |
| SMA 50 | +12.41% |
| SMA 200 | +40.24% |
| RSI (14) | 59.3 |
| Vol 30D | 42.1% |
| Vol 90D | 37.5% |
| 1Y Range | 81–166 |
| Daily bars | 536 |
| Perf Week | −1.00% |
| Perf Month | +4.03% |
| Perf Quarter | +43.40% |
| Perf Half Y | +62.45% |
| Perf Year | +65.70% |
| Perf YTD | +55.90% |
| Prev Day | +0.25% |
| Clavix | B |
| Debt / Eq | 0.54 |
| Curr Ratio | 1.68 |
| Int Cover | 3.5× |
| FCF Margin | 17.8% |
| Rev Growth | +3.7% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 10 / 19 |
What RVTY does
Revvity, Inc. provides health sciences solutions, technologies, and services.
The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.
It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names.
The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023.
Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Clavix risk grade
regraded every trading dayRVTY grades B, 74.5 of 100. Steadiest on Sector Resilience (68), most exposed on Price Stability (57, mixed). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 10 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| RVTY | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.09 | 1.18 |
| Volatilityannualized | 27.3% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −30.1% | — |
| Typical daily movemedian absolute daily change | 1.38% | — |
| Days beyond ±3%of the last 252 sessions | 51 (20%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| RVTY | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.09 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| RVTY | |
|---|---|
| 1 week | −1.0% |
| 1 month | +4.0% |
| Year to date | +55.9% |
| 1 year | +65.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| RVTY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 4 Aug |
| Average score0 most bearish, 100 most bullish | 70 |
| Bullish · bearisharticles above 60 · below 40 | 27 · 1 |
| Directionarticles whose tone is improving vs worsening | 27 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| RVTY | |
|---|---|
| Revenue growthyear over year | +3.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openA Massachusetts appeals court upheld a lower court ruling that Cloud Software Group wrongly used a 'sham audit' to end a long-term software partnership and take its customers. The headline frames this as a win for Revvity involving roughly $4 million in fees, though the article body does not name Revvity directly.
An analyst-style article recommends holding Revvity (RVTY) stock, pointing to growth in its diagnostics business, rising demand tied to AI, and expansion in life sciences as reasons to stay invested, while flagging headwinds in China and pressure on profit margins as near-term concerns.
Revvity launched an automated screening kit in Europe, certified under the EU's rules for diagnostic devices, to detect Type 1 Diabetes in children. The product extends the company's existing newborn-screening platform into early-childhood testing.
Revvity has launched an EU-approved (CE-IVDR certified) automated screening kit for Type 1 Diabetes in children, extending its GSP screening platform beyond newborns into early childhood. The product is now available in Europe.
Revvity launched the GSP T1D 3plex kit, an automated test certified under European IVD regulations that screens children for risk of developing Type 1 diabetes before symptoms appear.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MEDP | Medpace Holdings Inc | B | $17.26B | 35.12 | 1.11 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.33B | — | 1.37 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 49.78 | 1.15 | Compare |
| TEM | Tempus AI Inc | D- | $11.68B | — | 2.37 | Compare |
| TECH | Bio-Techne Corp | B | $11.38B | 62.58 | 1.28 | Compare |
| RGEN | Repligen Corp | B- | $11.14B | 268.12 | 1.14 | Compare |
| AVTR | Avantor Inc | B- | $11.11B | — | 0.97 | Compare |
| QGEN | Qiagen NV | B+ | $9.51B | 23.22 | 0.59 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.